Karyopharm Theraps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KARYOPHARM THERAPS, and what generic alternatives to KARYOPHARM THERAPS drugs are available?
KARYOPHARM THERAPS has one approved drug.
There are ten US patents protecting KARYOPHARM THERAPS drugs.
There are one hundred and sixteen patent family members on KARYOPHARM THERAPS drugs in thirty-eight countries and fifteen supplementary protection certificates in thirteen countries.
Summary for Karyopharm Theraps
International Patents: | 116 |
US Patents: | 10 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Karyopharm Theraps
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-003 | Apr 15, 2021 | RX | Yes | No | 11,787,771 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 8,999,996 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 10,519,139 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,034,660 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-004 | Apr 15, 2021 | RX | Yes | Yes | 11,753,401 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,753,401 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Karyopharm Theraps Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 111484483 | ⤷ Try a Trial |
Singapore | 10201808624V | ⤷ Try a Trial |
Ukraine | 115532 | ⤷ Try a Trial |
Australia | 2012290467 | ⤷ Try a Trial |
Chile | 2015001257 | ⤷ Try a Trial |
Poland | 2736887 | ⤷ Try a Trial |
Chile | 2014000224 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Karyopharm Theraps Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2736887 | PA2021007,C2736887 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326 |
2736887 | 29/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: SELINEXOR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1537 (MITTEILUNG) 20210329 |
2736887 | 2190030-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SELINEXOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1537 20210329 |
2736887 | C202130053 | Spain | ⤷ Try a Trial | PRODUCT NAME: SELINEXOR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1537; DATE OF AUTHORISATION: 20210326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1537; DATE OF FIRST AUTHORISATION IN EEA: 20210326 |
2736887 | CR 2021 00031 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329 |
2736887 | 301119 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
2736887 | 132021000000143 | Italy | ⤷ Try a Trial | PRODUCT NAME: SELIXENOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(NEXPOVIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1537, 20210329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.